

PTO/SB/21 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/643589	
	Filing Date	August 18, 2003	
	First Named Inventor	Debra D. Pittman	
	Art Unit	N/A	
	Examiner Name	Not Yet Assigned	
Total Number of Pages in This Submission	1	Attorney Docket Number	WYTH-P01-002

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	ROPES & GRAY LLP Anita Varma - 43,221
Signature	<i>Anita Varma</i>
Date	February 25, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: <u>2/25/04</u>	Signature: <u>Crena Soldano</u> (Crena Soldano)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 2/25/04

Signature: Crena Soldano

(Crena Soldano)

Docket No.: WYTH-P01-002
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Pittman et al.

Application No.: 10/643589

Confirmation No.: 3988

Filed: August 18, 2003

Art Unit: 1646

For: COMPOSITIONS AND METHODS FOR
TREATING RAGE-ASSOCIATED
DISORDERS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. WYTH-P01-002. A duplicate copy of this paper is enclosed.

Dated: February 25, 2004

Respectfully submitted,

By Anita Varma

Anita Varma

Registration No.: 43,221

ROPES & GRAY LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/643589
				Filing Date	August 18, 2003
				First Named Inventor	Debra D. Pittman
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	WYTH-P01-002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-5,864,018	01-26-1999	Schering Aktiengesellschaft	
	AB	US-5,891,341	04-06-1999	The Picower Institute for Medical Research	
	AC	US-6,007,865	12-28-1999	Alteon Inc.; The Picower Institute for Medical Research	
	AD	US-6,380,165-B1	04-30-2002	The Picower Institute for Medical Research	
	AE	US-6,440,749-B1	08-27-2002	Alteon, Inc.; The Picower Institute for Medical Research	
	AF	US-5,656,261	08-12-1997	The Picower Institute for Medical Research; Alteon Inc.	
	AG	US-5,853,703	12-29-1998	The Picower Institute for Medical Research; Alteon Inc.	
	AH	US-2001/0039256-A1	11-08-2001	Stern, et al.	
	AI	US-2001/0053357-A1	12-20-2001	Stern, et al.	
	AJ	US-2002/0002203-A1	01-03-2002	Rahbar	
	AK	US-2002/0013256-A1	01-31-2002	Rahbar, et al.	
	AL	US-2002/0022234-A1	02-21-2002	Al-Abed, et al.	
	AM	US-2002/0037496	03-28-2002	Jacobson, et al.	
	AN	US-2002/0077293-A1	06-20-2002	Cahoon, et al.	
	AO	US-2002/0082273-A1	06-27-2002	Bush, et al.	
	AP	US-2002/0086282-A1	07-04-2002	Pillarisetti, et al.	
	AQ	US-2002/0106726-A1	08-08-2002	Schmidt, et al.	
	AR	US-2002/0116725-A1	08-22-2002	Stern, et al.	
	AS	US-2002/0122799-A1	09-05-2002	Stern, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-00/18970-A1	04-06-2000	Asahi Kasei Kogyo Kabushiki Kaisha		
	BB	WO-00/20458-A1	04-13-2000	The Trustees of Columbia University in the City of New York		
	BC	WO-00/20621-A1	04-13-2000	The Trustees of Columbia University in The City of New York		
	BD	WO-01/05422-A1	01-25-2001	Biomerieux Stelhys		
	BE	WO-01/12598	02-22-2001	The Trustees of Columbia University in The City of New York		
	BF	WO-01/18060-A1	03-15-2001	Toray Industries, Inc.		
	BG	WO-01/029269	04-26-2001	Case Western Reserve University		
	BH	WO-01/76584	10-18-2001	City of Hope		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/643589
				Filing Date	August 18, 2003
				First Named Inventor	Debra D. Pittman
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	WYTH-P01-002

BI	WO-01/079849	10-25-2001	Trans Tech Pharma		
BJ	WO-01/086002	11-15-2001	Genetics Institute, LLC; The Rockefeller University		
BK	WO-01/92210-A1	12-06-2001	Trans Tech Pharma		
BL	WO-01/092892	12-06-2001	Transtech Pharma, Inc.		
BM	WO-02/30889	04-18-2002	The Trustees of Columbia University in The City of New York		
BN	WO-02/030889	04-18-2002	The Trustees of Columbia University in The City of New York		
BO	WO-02/066978	08-29-2002	Reddy US Therapeutics, Inc.		
BP	WO-02/068636-A1	09-06-2002	Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V.		
BQ	WO-02/14519-A1	02-21-2002	The Trustees of Columbia University in The City of New York		
BR	WO-97/26913-A1	07-31-1997	The Trustees of Columbia University in The City of New York		
BS	WO-97/39125-A1	10-23-1997	Schering Aktiengesellschaft Patente		
BT	WO-98/22138-A1	05-28-1998	The Trustees of Columbia University in The City of New York		
BU	WO-98/40071-A1	09-17-1998	The General Hospital Corporation		
BV	WO-99/07402-A1	02-18-1999	The Trustees of Columbia University of The City of New York		
BW	WO-99/18987-A1	04-22-1999	The Trustees of Columbia University of The City of New York		
BX	WO-99/45907-A2	09-16-1999	The General Hospital Corporation		
BY	WO-99/54485-A1	10-28-1999	The Trustees of Columbia University in The City of New York		
BZ	WO-97/39121-A1	10-23-1997	Schering Aktiengesellschaft		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Examiner Signature			Date Considered



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/643589
				Filing Date	August 18, 2003
				First Named Inventor	Debra D. Pittman
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	WYTH-P01-002
Sheet	3	of	3		

	CA	Schmidt, et al., "The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses," J. Clin. Invest. 949-955, Vol. 108(7), October 2001.	
--	----	---	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--